People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...
Negative Pressure Wound Therapy IndustryThe global negative pressure wound therapy (NPWT) market is projected to grow from an estimated valuation of USD 6.5 billion in 2023 to USD 10.8 billion by 2033 ...
The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...
Denovo Bioinnovations Pvt. Ltd. has secured ₹1.96 Crore from Campus Angels Network to advance its surgical robotics innovations. Founded by Dr. Nikhil Mamoria, Denovo develops cutting-edge wound ...